The landscape of drug discovery and development is witnessing a significant resurgence in covalent inhibitors, a class of therapeutics that…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
The pharmaceutical industry, known for its dynamic shifts and competitive landscape, has witnessed a seismic change at its pinnacle. Eli…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
The core of Amazon Bio Discovery lies in its ability to route AI-designed antibody candidates directly to leading DNA Synthesis…
Read More
OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…
Read More
Sai Life Sciences Plans to Recruit 700+ Professionals in FY27 as Indian CRDMO Demand Accelerates
Hyderabad, India – Sai Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced an ambitious…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, announced a landmark collaboration with pharmaceutical giant Eli…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Closing the Information Gap: ETH Zürich Team Integrates Function and Binding in One Drug Screening Assay
In a significant advancement poised to reshape the landscape of pharmaceutical development, a collaborative team from ETH Zürich and the…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
